Discovery of a Novel Scaffold As an Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B
Overview
Authors
Affiliations
Indoleamine 2,3-dioxygenase 1 (IDO1) has emerged as a key target for cancer therapy, as IDO1 plays a critical role in the capacity of tumor cells to evade the immune system. The pyrrolopiperazinone alkaloid longamide B and its derivatives were identified as novel IDO1 inhibitors based on docking studies and small library synthesis. The thioamide derivative showed higher IDO1 inhibitory activity than longamide B, and displayed an activity similar to that of a representative IDO1 inhibitor, 1-methyl-tryptophan. These results suggest that the pyrrolopiperazinone scaffold of longamide B could be used in the development of IDO1 inhibitors.
PbsNRs: predict the potential binders and scaffolds for nuclear receptors.
Zheng G, Wu D, Wei X, Xu D, Mao T, Yan D Brief Bioinform. 2025; 26(1.
PMID: 39798999 PMC: 11724720. DOI: 10.1093/bib/bbae710.
Accessing Chiral Pyrrolodiketopiperazines under Organocatalytic Conditions.
Dunabeitia E, Landa A, Lopez R, Palomo C Org Lett. 2022; 25(1):125-129.
PMID: 36579971 PMC: 10018776. DOI: 10.1021/acs.orglett.2c03924.
Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources.
Tan Y, Liu M, Li M, Chen Y, Ren M Front Pharmacol. 2022; 13:1046818.
PMID: 36408235 PMC: 9672321. DOI: 10.3389/fphar.2022.1046818.
Zhang K, Tran C, Alami M, Hamze A, Provot O Pharmaceuticals (Basel). 2021; 14(8).
PMID: 34451876 PMC: 8399128. DOI: 10.3390/ph14080779.
Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays.
Ge H, Mao L, Zhao J, Wang Y, Shi D, Yang X J Comput Aided Mol Des. 2021; 35(5):679-694.
PMID: 33905074 DOI: 10.1007/s10822-021-00386-6.